A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma
Geoffrey Shouse(City Of Hope National Medical Center), Alexey V. Danilov(Dartmouth–Hitchcock Medical Center), Neil A. Bailey, Brian T. Hill(Cleveland Clinic), Jordan Gauthier(Fred Hutch Cancer Center), Deborah M. Stephens(University of North Carolina at Chapel Hill), Steven M. Bair(University of Colorado Cancer Center), Audrey M. Sigmund(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Krish Patel, Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Gordon Smilnak(Northwestern University), Max J. Gordon(Oregon Health & Science University), Andy Kaempf(Oregon Health & Science University), Mazyar Shadman(University of Washington), David Yashar(City Of Hope National Medical Center), Lindsey Fitzgerald(Huntsman Cancer Institute), Andrew Artz, Adam S. Kittai(The Ohio State University Wexner Medical Center), Samantha Jaglowski(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Agrima Mian(Cleveland Clinic), Reem Karmali(Northwestern University), Amneet Bajwa(The Ohio State University), Manali Kamdar(University of Colorado Cancer Center)
Cited by 49
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
|Nature Medicine|2020|593
Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
|Journal of Clinical Oncology|2018|574